Reviva to Seek Clearance for Phase 2 Trials of Brilaroxazine

Reviva to Seek Clearance for Phase 2 Trials of Brilaroxazine

312082

Reviva to Seek Clearance for Phase 2 Trials of Brilaroxazine

Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical trials testing its investigational therapy brilaroxazine in people with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). “We … expect to begin regulatory submissions to the FDA for pulmonary indications including IPF and PAH by the end of the first quarter of 2022,” Laxminarayan Bhat, PhD, Reviva’s founder, president, and CEO, said in a press…

You must be logged in to read/download the full post.